Fort Pitt Capital Group LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 2.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 25,633 shares of the company’s stock after buying an additional 504 shares during the period. Fort Pitt Capital Group LLC’s holdings in Johnson & Johnson were worth $3,739,000 as of its most recent SEC filing.
Several other institutional investors have also modified their holdings of JNJ. Dumont & Blake Investment Advisors LLC lifted its position in shares of Johnson & Johnson by 0.3% in the fourth quarter. Dumont & Blake Investment Advisors LLC now owns 20,796 shares of the company’s stock worth $3,033,000 after buying an additional 71 shares during the last quarter. DE Burlo Group Inc. increased its stake in shares of Johnson & Johnson by 3.9% in the fourth quarter. DE Burlo Group Inc. now owns 1,871 shares of the company’s stock worth $273,000 after purchasing an additional 71 shares during the period. Verus Financial Partners Inc. increased its stake in shares of Johnson & Johnson by 1.7% in the fourth quarter. Verus Financial Partners Inc. now owns 4,382 shares of the company’s stock worth $639,000 after purchasing an additional 74 shares during the period. Aries Wealth Management increased its stake in shares of Johnson & Johnson by 0.3% in the fourth quarter. Aries Wealth Management now owns 27,932 shares of the company’s stock worth $4,025,000 after purchasing an additional 75 shares during the period. Finally, AlphaMark Advisors LLC increased its stake in shares of Johnson & Johnson by 1.3% in the fourth quarter. AlphaMark Advisors LLC now owns 5,799 shares of the company’s stock worth $846,000 after purchasing an additional 75 shares during the period. 69.30% of the stock is owned by institutional investors and hedge funds.
In other Johnson & Johnson news, Director William D. Perez bought 500 shares of Johnson & Johnson stock in a transaction dated Friday, March 13th. The shares were acquired at an average cost of $127.69 per share, with a total value of $63,845.00. Following the acquisition, the director now directly owns 16,030 shares of the company’s stock, valued at $2,046,870.70. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Michael E. Sneed sold 58,128 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $149.39, for a total value of $8,683,741.92. Following the completion of the transaction, the chief operating officer now directly owns 107,511 shares in the company, valued at $16,061,068.29. The disclosure for this sale can be found here. 0.27% of the stock is owned by insiders.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $1.88 earnings per share for the quarter, beating analysts’ consensus estimates of $1.87 by $0.01. The company had revenue of $20.75 billion for the quarter, compared to the consensus estimate of $20.83 billion. Johnson & Johnson had a return on equity of 39.27% and a net margin of 22.18%. The company’s quarterly revenue was up 1.7% on a year-over-year basis. During the same period in the previous year, the business earned $1.97 earnings per share. Equities research analysts expect that Johnson & Johnson will post 9.03 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 25th were issued a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 3.16%. The ex-dividend date was Monday, February 24th. Johnson & Johnson’s payout ratio is currently 43.78%.
A number of research firms have recently commented on JNJ. Credit Suisse Group dropped their price objective on Johnson & Johnson from $170.00 to $159.00 and set an “outperform” rating on the stock in a research note on Friday, March 6th. Zacks Investment Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $158.00 price objective on the stock in a research note on Wednesday, December 18th. Raymond James lifted their price objective on Johnson & Johnson from $147.00 to $161.00 and gave the stock an “outperform” rating in a research note on Thursday, January 23rd. Cantor Fitzgerald reiterated a “buy” rating and issued a $168.00 price objective on shares of Johnson & Johnson in a research note on Thursday, January 23rd. Finally, Morgan Stanley upgraded Johnson & Johnson from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $145.00 to $170.00 in a research note on Tuesday, December 17th. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Johnson & Johnson presently has an average rating of “Buy” and an average target price of $162.33.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.